Noten Jianhua BTK inhibitor Obitini ICP-022 new drug listing application accepted
-
Last Update: 2020-06-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, it has been reported that the http://
high-selective and irreversible small molecule Bruton tyrosine kinase (BTK) inhibitor Obitini ICP-022 developed by Innocare has been accepted for theapplication for the market (NDA) for the treatment of recurrent/difficult to treat chronic lymphocytic leukemia (CLL)/small cell lymphoma (SLL)obutiniObtoini is one of the fastest-growingdrug(http://, preclinical data show that the drug is highly selective for BTK, reduces off-targeting and demonstrates good safetyin the KINOMEscan test for 456 kinases, btK was significantly inhibited by 1 mCurrently, Obbutini is conducting a number of clinicaltrials of different indications
(http://, including two registered studies in China to treat recurrent refractory CLL/SLL and relapse difficult to treat lymphoma, and three phase II trials for the treatment of marginal lymphoma (MZL), central nervous leukemia (CNSL) and Fahrenheit cyloproteinemia (WM)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
